Charles Duncan joins Vanda Pharmaceuticals (NASDAQ: VNDA) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director, with his initial term running until the company’s 2026 annual stockholders’ meeting. Under Vanda’s outside director compensation program, Dr. Duncan received an initial restricted stock unit award with a grant date value of $390,000 as of April 22, 2026, vesting in four equal annual installments while he serves on the board, and he will receive a $50,000 annual cash fee paid quarterly. Beginning with the 2026 annual meeting, he will be eligible for additional annual restricted stock unit awards with a grant date value of $260,000, vesting one year from grant, with all such awards becoming fully vested upon a change of control. Vanda states that Dr. Duncan is an independent director and has entered into its standard Delaware law indemnification agreement for directors.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after appointment: 7 directors
Independent directors: 6 directors
Initial RSU grant value: $390,000
+4 more
7 metrics
Board size after appointment
7 directors
Following Charles Duncan’s appointment
Independent directors
6 directors
Independence status of Vanda’s seven-member board
Initial RSU grant value
$390,000
Grant date value as of April 22, 2026 for Charles Duncan
Annual RSU grant value
$260,000
Value of RSU award after each annual meeting starting 2026
Annual cash retainer
$50,000
Cash fee for Charles Duncan’s board service, payable quarterly
Initial RSU vesting schedule
4 equal installments
Annual vesting starting April 22, 2027 while he serves
Annual RSU vesting period
1 year
Vesting period for each annual $260,000 RSU award
Key Terms
restricted stock unit, change of control, independent director, indemnification agreement, +1 more
5 terms
restricted stock unit financial
"Pursuant to the Company’s outside director compensation program, Dr. Duncan was granted an initial restricted stock unit award with a fixed grant date value equal to $390,000"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
change of control financial
"In the event of a change of control of the Company, the restricted stock units will become fully vested"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
independent director regulatory
"The Board has determined that Dr. Duncan is an independent director in accordance with applicable rules"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
indemnification agreement regulatory
"Dr. Duncan and the Company entered into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
outside director compensation program financial
"Pursuant to the Company’s outside director compensation program, Dr. Duncan was granted an initial restricted stock unit award"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2026
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (202 ) 734-3400
| Not Applicable | ||
| (Former Name or Former Address, if Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | |||||||
On April 22, 2026, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from six to seven members, effective immediately and appointed Charles C. Duncan, Ph.D., as a director of the Company to fill the vacancy created by the expansion. Dr. Duncan will serve as a Class II director with an initial term that will expire at the Company’s 2026 annual meeting of stockholders.
The full text of the press release announcing Dr. Duncan’s appointment to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Pursuant to the Company’s outside director compensation program, Dr. Duncan was granted an initial restricted stock unit award with a fixed grant date value equal to $390,000 as of April 22, 2026, with the number of shares of common stock underlying the award to be determined based on such value calculated in accordance with ASC 718. The restricted stock units will vest in four equal installments while Dr. Duncan continues to provide service as a member of the Board, with the first annual vest taking place on April 22, 2027. In the event of a change of control of the Company, the restricted stock units will become fully vested. Dr. Duncan will also receive a $50,000 annual fee, payable quarterly. In addition, he will be eligible to receive, upon the conclusion of each annual meeting of stockholders beginning in 2026, an additional restricted stock unit award with a fixed grant date value equal to $260,000 as of the date of the annual meeting, with the number of shares of common stock underlying the award to be determined based on such value calculated in accordance with ASC 718. Such annual restricted stock units will vest one year from the date of grant, except that in the event of a change of control of the Company the restricted stock units will become fully vested. The outside director compensation program will be described in further detail in the Company’s Definitive Proxy Statement for its 2026 annual meeting of stockholders to be filed with the Securities and Exchange Commission.
Dr. Duncan and the Company entered into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted under Delaware law with respect to his service as a director. The indemnification agreement is in the form entered into with the Company’s other directors and executive officers. This form is filed as Exhibit 10.11 to the Company’s Registration Statement on Form S-1 (File No. 333-130759), as originally filed on December 29, 2005.
Since the beginning of the last fiscal year, there have been no related party transactions between the Company and Dr. Duncan that would be reportable under Item 404(a) of Regulation S-K.
The Board has determined that Dr. Duncan is an independent director in accordance with applicable rules of the Securities and Exchange Commission and The Nasdaq Global Market.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release of Vanda Pharmaceuticals Inc. dated April 22, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: | April 22, 2026 | VANDA PHARMACEUTICALS INC. | |||||||||||||||
| By: | /s/ Kevin Moran | ||||||||||||||||
| Name: | Kevin Moran | ||||||||||||||||
| Title: | Senior Vice President, Chief Financial Officer and Treasurer | ||||||||||||||||
Exhibit 99.1
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan’s appointment, Vanda’s Board of Directors is now comprised of seven directors, six of whom are independent.
Dr. Duncan is a highly experienced and respected leader in the life sciences and biotechnology sector,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board. “We are excited to welcome him to our strong and independent Board of Directors, where his deep industry expertise will complement our strengths as we advance our innovative pipeline in the service of patient needs.”
Dr. Duncan currently serves as the President of Sulci Advisors, LLC, a business advisory firm focused on the life sciences sector, a position he has held since founding the firm in September 2025. Prior to founding Sulci Advisors, LLC, Dr. Duncan spent nearly three decades as a sell-side biotechnology equity research analyst. From July 2018 until his retirement in June 2025, Dr. Duncan served as Managing Director and Senior Biotechnology Analyst at Cantor Fitzgerald & Co., where he initiated or assumed coverage on more than 70 companies, with a particular focus on neurology, psychiatry and platform-enabled therapeutics. From December 2012 to June 2018, Dr. Duncan served as Managing Director and Senior Biotechnology Analyst at Piper Jaffray & Co., where he initiated or assumed coverage on more than 40 companies and was recognized by Thomson Reuters StarMine for stock picking and earnings estimates. From September 2002 to December 2012, Dr. Duncan served as Managing Director, Supervisory and Senior Biotechnology Analyst at JMP Securities, LLC, where he was a founding healthcare partner and launched the firm’s biotechnology research franchise.
Earlier in his career, Dr. Duncan held biotechnology equity research positions at Dresdner Kleinwort Wasserstein Securities, Inc., Prudential Securities, Inc., Tucker Anthony Cleary Gull, Inc. and Chatfield Dean & Co., Inc., and previously served as a founder and board member of InfusionVision MEDical, Inc., a private venture capital-backed medical device company.
Dr. Duncan received his Ph.D. in Pharmaceutical Sciences, with a concentration in Neuropharmacology, from the University of Colorado-Boulder and his B.S. in Zoology from the University of Wisconsin-Madison.
Dr. Duncan joins the Vanda Pharmaceuticals board with broad industry perspectives and well-established experience translating clinical data and development plans for value creation to a diverse range of biotech stakeholders. “I am enthusiastic to join the Vanda board, especially at this potentially transformational period in the company’s evolution,” said Dr. Duncan. “Having covered a large number of Neuro-Innovator companies during my sell-side career, I see Vanda having a long history of innovation within CNS disorders, and it has served well patients in need. That said, with recent approvals of NEREUS™ and BYSANTI™, previous label expansion for Fanapt® and a growing pipeline to deliver impactful data over the next ~12 months, I believe Vanda has entered a new era of growth. I look forward to productive board service as management strives to create value broadly for stakeholders, including patients, payors, and shareholders.”
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, without limitation, statements regarding Dr. Duncan’s ability to assist Vanda in advancing its product pipeline in the service of patient needs, the delivery of impactful data over the next 12 months, Vanda’s growth and the creation of value for stakeholders are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and
uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s assumptions regarding its ability to complete the clinical development and obtain regulatory approval for the products in its pipeline, the success of Vanda’s clinical trials over the next 12 months and Vanda’s ability to report positive results from the trials during such period, Vanda’s ability to continue to grow its pipeline and portfolio of products and management’s ability to create value for patients, payors and shareholders. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
SOURCE Vanda Pharmaceuticals Inc.
FAQ
What change did Vanda Pharmaceuticals (VNDA) make to its Board of Directors?
Vanda Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director. His initial term runs until the company’s 2026 annual meeting of stockholders, increasing independent oversight on the board.
How is new Vanda director Charles Duncan compensated for board service?
Charles Duncan receives an initial restricted stock unit grant valued at $390,000, vesting in four equal annual installments, plus a $50,000 annual cash fee paid quarterly. He is also eligible for recurring annual RSU awards valued at $260,000 following each annual meeting, starting in 2026.
When do Charles Duncan’s Vanda restricted stock units vest?
The initial $390,000 restricted stock unit award vests in four equal yearly installments while he serves as a director, with the first vesting on April 22, 2027. Future annual RSU grants of $260,000, beginning in 2026, vest one year after their grant date.
What happens to Charles Duncan’s Vanda equity awards if there is a change of control?
In the event of a change of control of Vanda Pharmaceuticals, all restricted stock units granted to Charles Duncan under the outside director compensation program become fully vested. This applies to both his initial $390,000 grant and any subsequent annual $260,000 awards.
Is Charles Duncan considered an independent director at Vanda Pharmaceuticals (VNDA)?
Yes. Vanda’s Board determined that Charles Duncan qualifies as an independent director under applicable Securities and Exchange Commission rules and The Nasdaq Global Market standards. This means he meets regulatory independence criteria for serving on the company’s board.
Does Vanda provide indemnification protection to Charles Duncan as a director?
Yes. Charles Duncan entered into Vanda’s standard indemnification agreement for directors, requiring the company to indemnify him to the fullest extent permitted under Delaware law. The agreement mirrors the form used for Vanda’s other directors and executive officers.